Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 2
2005 1
2007 2
2008 4
2009 2
2010 4
2011 4
2012 2
2013 2
2014 3
2015 3
2016 4
2017 5
2018 7
2019 9
2020 22
2021 12
2022 18
2023 11
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

107 results

Results by year

Filters applied: . Clear all
Page 1
Surrogate endpoints for overall survival in randomized clinical trials testing immune checkpoint inhibitors: a systematic review and meta-analysis.
Sala I, Pagan E, Pala L, Oriecuia C, Musca M, Specchia C, De Pas T, Cortes J, Giaccone G, Postow M, Gelber RD, Bagnardi V, Conforti F. Sala I, et al. Among authors: pala l. Front Immunol. 2024 Jan 29;15:1340979. doi: 10.3389/fimmu.2024.1340979. eCollection 2024. Front Immunol. 2024. PMID: 38348030 Free PMC article.
Fine-Tuning Adjuvant Endocrine Therapy for Early-Stage Breast Cancer: An Expert Consensus on Open Issues for Future Research.
Conforti F, Pala L, De Pas T, Zattarin E, Catania C, Cocorocchio E, Rossi G, Laszlo D, Colleoni M, Zambelli A, Hortobagyi GN, Cortes J, Piccart MJ, Dowsett M, Gelber RD, Viale G. Conforti F, et al. Among authors: pala l. Clin Cancer Res. 2024 Mar 15;30(6):1093-1103. doi: 10.1158/1078-0432.CCR-23-1836. Clin Cancer Res. 2024. PMID: 37906083
Improved outcomes in women with BRAF-mutant melanoma treated with BRAF/MEK-targeted therapy across randomized clinical trials. A systematic review and meta-analysis.
Pala L, De Pas T, Pagan E, Minucci S, Catania C, Digiacomo N, Cocorocchio E, Laszlo D, Di Muzio A, Barigazzi C, Stucchi E, De Grandi L, Stucchi S, Viale G, Gelber RD, Bagnardi V, Conforti F. Pala L, et al. Semin Oncol. 2023 Feb-Apr;50(1-2):34-39. doi: 10.1053/j.seminoncol.2023.03.003. Epub 2023 Mar 21. Semin Oncol. 2023. PMID: 36967333 Review.
Corrigendum to 'Chemotherapy in patients with localized angiosarcoma of any site: A retrospective european study' [Eur J Cancer 171 (2022) 183-192].
Conforti F, Gronchi A, Penel N, Jones RL, Broto JM, Sala I, Bagnardi V, Napolitano A, Pala L, Pennacchioli E, Catania C, Queirolo P, Grigani G, Merlini A, Stacchiotti S, Comandone A, Vincenzi B, Quagliuolo V, Bertuzzi A, Boglione A, Palassini E, Baldi GG, Blay JY, Ryckewaert T, Toulmonde M, Italiano A, Le Cesne A, Ray-Coquard I, Cruz J, Hernández-León CN, Trufero JM, da Silva Moura D, Muñiz NH, De Pas T. Conforti F, et al. Among authors: pala l. Eur J Cancer. 2023 May;184:197-198. doi: 10.1016/j.ejca.2022.11.027. Epub 2023 Mar 10. Eur J Cancer. 2023. PMID: 36907702 No abstract available.
Tailoring the optimal duration of the extended adjuvant endocrine therapy in patients with early-stage breast cancer. A systematic review and meta-analysis of randomized clinical trials.
Pala L, De Pas T, Pagan E, Sala I, Catania C, Zattarin E, Arnone P, Grassi MM, Colleoni M, Wolff AC, Cortes J, Piccart M, Gelber RD, Viale G, Bagnardi V, Conforti F. Pala L, et al. Breast. 2023 Jun;69:258-264. doi: 10.1016/j.breast.2023.02.012. Epub 2023 Mar 2. Breast. 2023. PMID: 36898259 Free PMC article.
Orthorexia nervosa and type 1 diabetes: results of a cross-sectional study.
Cosentino C, Rossi E, Pala L, Lelmi R, Campanino C, Ricca V, Mannucci E, Dicembrini I, Rotella F. Cosentino C, et al. Among authors: pala l. Acta Diabetol. 2023 May;60(5):681-686. doi: 10.1007/s00592-023-02044-9. Epub 2023 Feb 20. Acta Diabetol. 2023. PMID: 36806923
107 results